首页膀胱肿瘤诊断证据详情

The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta-analysis

原文: 2021 年 发布于 Urol Oncol 28 卷 第 9-10 期 523-535 浏览量:233次

作者: Liao Y. H. Tang H. Q. Wang M. M. Wang K. K. Wang Y. Z. Jiang N.

作者单位: Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Department of Urology, University of Iowa, Iowa City, IA, USA. Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. Department of Urology, Groupe Hospitalier Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Faculty of Medicine Pierre et Marie Curie, University Paris Sorbonne, Paris, France. Royal Hallamshire Hospital and University of Sheffield, Sheffield, UK. Department of Pathology, Tenon Hospital, AP-HP, University Pierre and Marie Curie, Paris, France. Department of Immunology, Institut Pasteur and INSERM U1223, Paris, France. EAU Research Foundation, EAU Central Office, Arnhem, The Netherlands. The Greenberg Bladder Cancer Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA. Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.

归属分类: 膀胱肿瘤诊断证据

DOI: 10.3389/fonc.2019.00981

关键词: Data Systems Humans *Multiparametric Magnetic Resonance Imaging Neoplasm Invasiveness Predictive Value of Tests Reproducibility of Results Urinary Bladder Neoplasms/*diagnostic imaging/pathology Bladder cancer Magnetic resonance imaging Meta-analysis Muscle invasive Systematic review Vesical Imaging Reporting and Data System

文献简介

OBJECTIVES: To systematically summarise the available evidence on urinary bladder cancer (BC) mutation markers. Gene mutations are expected to provide novel biomarkers for urinary BC diagnosis. To date, evidence on urinary BC mutation markers has not proven sufficient to be adopted by clinical guidelines. In the present systematic review, diagnostic accuracy of urinary mutation analysis is separately assessed for primary BC diagnosis (BC detection) and for follow-up of BC patients (BC surveillance). METHODS: A literature search (PubMed, Embase.com and Wiley/Cochrane Library) and systematic review was performed up to 31 October 2019. As studies were too heterogeneous, no quantitative analysis could be performed. RESULTS: In total, 25 studies were summarised by qualitative analysis. For BC detection, diagnostic accuracy differed considerably for single mutation markers (sensitivity 1-85%, specificity 84-100%), and for marker panels (sensitivity 50-94%, specificity 43-97%). Similarly, for BC surveillance, diagnostic accuracy was highly variable for single mutation markers (sensitivity 0-85%, specificity 66-100%), and for marker panels (sensitivity 51-84%, specificity 66-96%). CONCLUSION: Urinary mutation analysis showed to be a promising diagnostic tool for non-invasive BC diagnosis. Nonetheless, we observed substantial differences in diagnostic accuracy of urinary BC mutation markers among publications. To translate the data summarised in the present review to future clinical practice, heterogeneity in research design, BC population, mutation analysis technique and urinary DNA should be considered. Eventual clinical implementation of urinary BC mutation markers can only be achieved by collecting more and stronger evidence. Combining different molecular assays might overcome current shortcomings of urinary mutation analysis.

热门文献